BMS-986179

BMS-986179 is a human monoclonal antibody that targets and binds to CD73, an ecto-5'-nucleotidase expressed on various cell types. By binding to CD73, BMS-986179 induces clustering and internalization of the protein, thereby inhibiting its enzymatic activity. This prevents the conversion of extracellular adenosine monophosphate (AMP) to adenosine, reducing immunosuppressive adenosine levels in the tumor microenvironment. The drug was developed by Bristol Myers Squibb for use as an antineoplastic agent and immunotherapy in solid tumors[1][2][3][5]. Its mechanism includes inhibition of 5'-nucleotidase activity (CD73), stimulation of T lymphocytes, and potential induction of antibody-dependent cell cytotoxicity[5].

Other names

anti-CD73 monoclonal antibody BMS-986179anti-CD-73 monoclonal antibody BMS-986179anti-CD 73 monoclonal antibody BMS-986179